--

Dr. Ali Chamseddine is a Consultant Medical Oncologist from France, holding dual board certifications in medical oncology and clinical haematology, as well as MD and PhD degrees. He gained expertise at the esteemed Gustave Roussy Cancer Center in Villejuif, France, where he served as a senior medical oncology consultant. Dr. Chamseddine further honed his skills through a post-doctoral fellowship at the Division of Cancer Medicine, Leukaemia Department, at the renowned MD Anderson Cancer Center in Houston, Texas, USA.

Throughout his career, Dr. Chamseddine has been deeply involved in research, with over 50 publications in prestigious journals, including the New England Journal of Medicine. Dr. Chamseddine's clinical expertise spans various areas of oncology, with a primary focus on Precision Oncology, Gastrointestinal Tumours, Breast and Genitourinary Tumours, and Lung Cancer.

He is an active member of esteemed professional organisations such as the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), and the European Hematology Association (EHA), among others.

Dr. Chamseddine's specific areas of interest include gastrointestinal cancers, breast cancer, genitourinary cancers, lung cancer, gynecologic cancers, central nervous system cancers, and soft-tissue sarcomas. He is also deeply committed to palliative and supportive care in cancer patients. Dr. Chamseddine focuses on developing patient-centric and personalised treatment approaches, identifying predictive markers for better benefit-risk balance of anticancer drugs, and implementing liquid biopsy for improved molecular characterization of cancers.